Management Team

Lee Schalop, M.D.

Chief Executive Officer

Lee Schalop is a co-founder of Oncoceutics. He served as the company’s Chief Operating Officer from 2016 to 2020 and as the Chief Business Officer from the company’s founding in 2009 until 2016.  Prior to Oncoceutics, Dr. Schalop attended the Albert Einstein College of Medicine, graduating with a doctor of medicine degree in 2008.  Prior to attending medical school, Dr. Schalop spent more than 19 years in the financial industry at a number of major Wall Street firms, including Morgan Stanley, J.P. Morgan, Credit Suisse and Banc of America Securities. From 1985 to 1993, he was an investment banker and his fund raising activities included more than 10 initial public offerings, the largest of which raised over $700 million. From 1993 to 2004, he served as a research analyst and authored more than 1,000 reports covering more than 50 different publicly traded companies, earning a reputation for groundbreaking research. Lee also sits on the advisory board of the Vagelos Program in Life Sciences and Management at the University of Pennsylvania. He is a summa cum laude graduate of the University of Pennsylvania where he earned dual degrees from the University’s Wharton School and College of Arts and Sciences.

Martin Stogniew, Ph.D.

Chief Development Officer

Martin Stogniew brings 33 years of senior executive experience in the pharmaceutical industry and has served as an independent member of the Board of Director for Provid Pharmaceuticals. Dr. Stogniew has made significant contributions resulting in FDA approval of nine New Drug Applications, issuance of 28 US patents, and closure of four major M&A deals valued at $3 billion. Formerly, he was Executive Vice President, Chief Technology Officer of Prestwick Pharmaceuticals and was accountable for all technical and regulatory diligence during the sale of the company to Biovail in 2008. Previously he was Executive Vice President, Scientific Affairs for Vicuron Pharmaceuticals where he played an integral part in the 2005 sale to Pfizer for $1.9B. He was Vice President, Pharmaceutical Sciences for U.S. Bioscience, where he played a key role in the sale to Medimmune. Dr. Stogniew completed a postdoctoral fellowship at The Johns Hopkins University, School of Medicine, earned a Ph.D. in Medicinal Chemistry from the University of Maryland and received a BS in Pharmacy with honors from the University of Maryland. He started with Oncoceutics in 2012.


Joshua Allen, Ph.D.

Chief Scientific Officer

Joshua Allen discovered ONC201 and co-invented the imipridone class of compounds. He directed the preclinical studies that identified ONC201 as an anti-cancer agent, defined its preclinical profile, elucidated its novel mechanism of action, and extended its pharmacophore into a new class of therapies. Dr. Allen received his Ph.D. in Biochemistry and Molecular Biophysics from the University of Pennsylvania and completed a post-doctoral fellowship in pharmacology at the Penn State Cancer Institute. Dr. Allen has authored several research publications and awarded grants for preclinical and clinical development of novel therapies and biomarkers. Several awards have recognized his entrepreneurial research and development efforts in different areas of oncology, including recognition on the 2016 Forbes 30 under 30 list. Dr. Allen joined Oncoceutics in 2012.